AP2249A - Use of oxycodone for treating visceral pain. - Google Patents

Use of oxycodone for treating visceral pain.

Info

Publication number
AP2249A
AP2249A AP2007004057A AP2007004057A AP2249A AP 2249 A AP2249 A AP 2249A AP 2007004057 A AP2007004057 A AP 2007004057A AP 2007004057 A AP2007004057 A AP 2007004057A AP 2249 A AP2249 A AP 2249A
Authority
AP
ARIPO
Prior art keywords
oxycodone
visceral pain
treating visceral
treating
pain
Prior art date
Application number
AP2007004057A
Other languages
English (en)
Other versions
AP2007004057A0 (en
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AP2007004057A0 publication Critical patent/AP2007004057A0/xx
Application granted granted Critical
Publication of AP2249A publication Critical patent/AP2249A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
AP2007004057A 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain. AP2249A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (2)

Publication Number Publication Date
AP2007004057A0 AP2007004057A0 (en) 2007-08-31
AP2249A true AP2249A (en) 2011-07-18

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004057A AP2249A (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain.

Country Status (32)

Country Link
US (2) US20080200493A1 (zh)
EP (1) EP1838318B1 (zh)
JP (1) JP5049139B2 (zh)
KR (10) KR20200128451A (zh)
CN (1) CN101106996B (zh)
AP (1) AP2249A (zh)
AR (1) AR052880A1 (zh)
AT (2) ATE446092T1 (zh)
AU (1) AU2006207498B2 (zh)
BR (1) BRPI0606247A2 (zh)
CA (1) CA2595043C (zh)
CY (1) CY1109660T1 (zh)
DE (2) DE602006009899D1 (zh)
DK (2) DK1838318T3 (zh)
EA (1) EA013544B1 (zh)
ES (1) ES2333901T3 (zh)
HK (1) HK1107933A1 (zh)
HR (1) HRP20090679T1 (zh)
IL (1) IL184530A (zh)
ME (1) ME01066B (zh)
MX (1) MX2007007207A (zh)
MY (1) MY144471A (zh)
NO (1) NO338968B1 (zh)
NZ (1) NZ555852A (zh)
PL (1) PL1838318T3 (zh)
PT (1) PT1838318E (zh)
RS (1) RS51069B (zh)
SI (1) SI1838318T1 (zh)
TW (1) TWI432196B (zh)
UA (1) UA85471C2 (zh)
WO (1) WO2006077212A1 (zh)
ZA (1) ZA200705231B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
BRPI0907135B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
DK2710039T3 (en) 2011-05-20 2019-04-01 Alderbio Holdings Llc ANTI-CGRP COMPOSITIONS AND APPLICATION THEREOF
SG194973A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
JP6937368B2 (ja) 2016-09-23 2021-09-22 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 難治性片頭痛の治療方法
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
WO2002087512A2 (en) * 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
EP1449531A2 (en) * 1994-11-04 2004-08-25 Euro-Celtique Melt-extruded orally administrable opioid formulations
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
EP1449531A2 (en) * 1994-11-04 2004-08-25 Euro-Celtique Melt-extruded orally administrable opioid formulations
US5945416A (en) * 1996-03-25 1999-08-31 Eli Lilly And Company Method for treating pain
WO2002087512A2 (en) * 2001-05-02 2002-11-07 Euro-Celtique, S.A. Once-a-day oxycodone formulations
US20040254156A1 (en) * 2003-06-10 2004-12-16 Bertrand Le Bourdonnec Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
CY1109660T1 (el) 2014-08-13
BRPI0606247A2 (pt) 2009-06-09
JP5049139B2 (ja) 2012-10-17
KR20120089710A (ko) 2012-08-13
DK1838318T3 (da) 2010-01-04
JP2008526927A (ja) 2008-07-24
WO2006077212A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
KR20190135557A (ko) 2019-12-06
KR20210131450A (ko) 2021-11-02
TWI432196B (zh) 2014-04-01
KR20200128451A (ko) 2020-11-12
EA200701541A1 (ru) 2008-02-28
CN101106996A (zh) 2008-01-16
CA2595043C (en) 2013-11-19
CN101106996B (zh) 2013-10-23
NO20074174L (no) 2007-10-17
NZ555852A (en) 2010-01-29
KR20230170811A (ko) 2023-12-19
AU2006207498A1 (en) 2006-07-27
KR20220165797A (ko) 2022-12-15
ZA200705231B (en) 2008-06-25
AT9895U1 (de) 2008-05-15
ES2333901T3 (es) 2010-03-02
RS51069B (sr) 2010-10-31
KR20080106991A (ko) 2008-12-09
AP2007004057A0 (en) 2007-08-31
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
PT1838318E (pt) 2009-12-15
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DK200700207U1 (da) 2007-08-24
ME01066B (me) 2012-10-20
AU2006207498B2 (en) 2009-11-19
EA013544B1 (ru) 2010-06-30
MY144471A (en) 2011-09-30
IL184530A (en) 2015-01-29
KR20170021905A (ko) 2017-02-28
NO338968B1 (no) 2016-11-07
MX2007007207A (es) 2007-08-15
DE602006009899D1 (de) 2009-12-03
KR20070100368A (ko) 2007-10-10
DK200700207U3 (da) 2007-09-28
AR052880A1 (es) 2007-04-11
DE202006019887U1 (de) 2007-07-26
CA2595043A1 (en) 2006-07-27
SI1838318T1 (sl) 2010-02-26
IL184530A0 (en) 2007-10-31
TW200637554A (en) 2006-11-01
HRP20090679T1 (hr) 2010-01-31
PL1838318T3 (pl) 2010-03-31
KR20140091782A (ko) 2014-07-22
US20080200493A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
AP2249A (en) Use of oxycodone for treating visceral pain.
IL188430A0 (en) Treatment of tumors
GB0610867D0 (en) Treatment of pain
HK1131141A1 (en) Imidazolothiazole compounds for the treatment of disease
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
EP1709900A4 (en) ENDOSCOPE TREATMENT SYSTEM
GB0503380D0 (en) Tissue treatment system
IL193748A0 (en) Treatment of pain
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
EP1928452A4 (en) USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
EP1736093A4 (en) ENDOSCOPIC TREATMENT SYSTEM
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
GB0610868D0 (en) Treatment of pain
GB0511769D0 (en) Treatment
GB0621587D0 (en) Sludge treatment
GB0503382D0 (en) Tissue treatment system
GB0400802D0 (en) Compounds for the treatment of disease
EP1878443A4 (en) THERAPEUTIC AGENT FOR NEUROPATHIC PAIN
GB0616450D0 (en) Treatment of pain
GB0412262D0 (en) Use of compounds for the treatment of pain
GB0518003D0 (en) Treatment of hepatatis c
GB0521207D0 (en) Effluent treatment